Royal Bank of Canada
BCTX

Royal Bank of Canada’s Briacell Therapeutics BCTX Stock Holding History

Royal Bank of Canada’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1K Buy
289
+189
+189% +$696 ﹤0.01% 7208
2026
Q1 		$0 Hold
100
– – ﹤0.01% 7111
2025
Q4 		$1K Hold
100
– – ﹤0.01% 6964
2025
Q3 		$1K Sell
100
-7
-7% -$74 ﹤0.01% 6950
2025
Q2 		$3K Buy
107
+7
+7% +$255 ﹤0.01% 6722
2025
Q1 		$4K Buy
+100
New +$4.77K ﹤0.01% 6392
2024
Q4 		– Sell
-25
Closed -$5K – 6892
2024
Q3 		$5K Sell
25
-1
-4% -$112 ﹤0.01% 6485
2024
Q2 		$4K Buy
26
+2
+8% +$566 ﹤0.01% 6569
2024
Q1 		$10K Sell
24
-100
-81% -$55.1K ﹤0.01% 6188
2023
Q4 		$109K Buy
124
+100
+417% +$71.8K ﹤0.01% 5559
2023
Q3 		$23K Hold
24
– – ﹤0.01% 6122
2023
Q2 		$23K Buy
+24
New +$23.7K ﹤0.01% 6133
2023
Q1 		– Sell
-1
Closed -$1K – 7070
2022
Q4 		$1K Buy
+1
New +$847 ﹤0.01% 6999
2022
Q3 		– Sell
-1
Closed -$1K – 7436
2022
Q2 		$1K Buy
+1
New +$988 ﹤0.01% 7087
2022
Q1 		– Sell
-2
Closed -$3K – 7723
2021
Q4 		$3K Buy
+2
New +$2.62K ﹤0.01% 7322
2021
Q3 		– Hold
0
– – – 7624
2021
Q2 		– Hold
0
– – – 7471
2021
Q1 		– Hold
0
– – – 7414

Other funds holding BCTX

CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
LCM
LuminArx Capital Management New York $224M AUM
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

Royal Bank of Canada's BCTX Position: Q2 2026 in Review

Royal Bank of Canada increased its Briacell Therapeutics (BCTX) stake by 189% in Q2 2026, buying an estimated $696 and bringing the position to 289 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #7208.

Royal Bank of Canada first reported a position in BCTX in Q4 2021 and has held it in 15 quarters since. The position peaked at $109K in Q4 2023. 19 funds tracked by Wall St. Rank hold BCTX as of Q2 2026.

  • Royal Bank of Canada held 289 shares of Briacell Therapeutics worth $1K as of Q2 2026.
  • Royal Bank of Canada bought 189 Briacell Therapeutics shares in Q2 2026, an estimated $696.
  • Briacell Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #7208 holding.
  • Royal Bank of Canada first reported a position in Briacell Therapeutics in Q4 2021 and has held it in 15 quarters since.
  • Royal Bank of Canada's Briacell Therapeutics position peaked at $109K in Q4 2023.
  • 19 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.